
Sean E. Aeder
Examiner (ID: 2139, Phone: (571)272-8787 , Office: P/1642 )
| Most Active Art Unit | 1642 |
| Art Unit(s) | 1642 |
| Total Applications | 1939 |
| Issued Applications | 907 |
| Pending Applications | 201 |
| Abandoned Applications | 855 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 13677763
[patent_doc_number] => 20160377615
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-12-29
[patent_title] => METHOD FOR EVALUATION OF FUNCTION OF PHAGOCYTE
[patent_app_type] => utility
[patent_app_number] => 15/258531
[patent_app_country] => US
[patent_app_date] => 2016-09-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11197
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15258531
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/258531 | Method for evaluation of function of phagocyte | Sep 6, 2016 | Issued |
Array
(
[id] => 17028486
[patent_doc_number] => 11090284
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-08-17
[patent_title] => Ovarian cancer vaccines
[patent_app_type] => utility
[patent_app_number] => 15/757151
[patent_app_country] => US
[patent_app_date] => 2016-09-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 23
[patent_figures_cnt] => 20
[patent_no_of_words] => 16736
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 64
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15757151
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/757151 | Ovarian cancer vaccines | Sep 1, 2016 | Issued |
Array
(
[id] => 11337842
[patent_doc_number] => 20160363596
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-12-15
[patent_title] => 'SIGNATURES AND DETERMINANTS ASSOCIATED WITH PROSTATE CANCER PROGRESSION AND METHODS OF USE THEREOF'
[patent_app_type] => utility
[patent_app_number] => 15/248474
[patent_app_country] => US
[patent_app_date] => 2016-08-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 61
[patent_figures_cnt] => 61
[patent_no_of_words] => 41147
[patent_no_of_claims] => 89
[patent_no_of_ind_claims] => 49
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15248474
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/248474 | SIGNATURES AND DETERMINANTS ASSOCIATED WITH PROSTATE CANCER PROGRESSION AND METHODS OF USE THEREOF | Aug 25, 2016 | Abandoned |
Array
(
[id] => 13389123
[patent_doc_number] => 20180246104
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-08-30
[patent_title] => METHOD FOR DETECTING CIRCULATING TUMOR CELLS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 15/753301
[patent_app_country] => US
[patent_app_date] => 2016-08-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8642
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15753301
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/753301 | METHOD FOR DETECTING CIRCULATING TUMOR CELLS AND USES THEREOF | Aug 17, 2016 | Abandoned |
Array
(
[id] => 11421371
[patent_doc_number] => 20170029515
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-02-02
[patent_title] => 'METHOD OF INHIBITION OF LEUKEMIC STEM CELLS'
[patent_app_type] => utility
[patent_app_number] => 15/233260
[patent_app_country] => US
[patent_app_date] => 2016-08-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 28
[patent_figures_cnt] => 28
[patent_no_of_words] => 21453
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15233260
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/233260 | METHOD OF INHIBITION OF LEUKEMIC STEM CELLS | Aug 9, 2016 | Abandoned |
Array
(
[id] => 11336731
[patent_doc_number] => 20160362486
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-12-15
[patent_title] => 'SELF-BUFFERING PROTEIN FORMULATIONS'
[patent_app_type] => utility
[patent_app_number] => 15/231490
[patent_app_country] => US
[patent_app_date] => 2016-08-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 15
[patent_no_of_words] => 31302
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15231490
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/231490 | SELF-BUFFERING PROTEIN FORMULATIONS | Aug 7, 2016 | Abandoned |
Array
(
[id] => 11336730
[patent_doc_number] => 20160362485
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-12-15
[patent_title] => 'SELF-BUFFERING PROTEIN FORMULATIONS'
[patent_app_type] => utility
[patent_app_number] => 15/230039
[patent_app_country] => US
[patent_app_date] => 2016-08-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 15
[patent_no_of_words] => 31282
[patent_no_of_claims] => 31
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15230039
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/230039 | SELF-BUFFERING PROTEIN FORMULATIONS | Aug 4, 2016 | Abandoned |
Array
(
[id] => 11289170
[patent_doc_number] => 20160339102
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-11-24
[patent_title] => 'SELF-BUFFERING PROTEIN FORMULATIONS'
[patent_app_type] => utility
[patent_app_number] => 15/228955
[patent_app_country] => US
[patent_app_date] => 2016-08-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 15
[patent_no_of_words] => 31304
[patent_no_of_claims] => 31
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15228955
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/228955 | SELF-BUFFERING PROTEIN FORMULATIONS | Aug 3, 2016 | Abandoned |
Array
(
[id] => 11336729
[patent_doc_number] => 20160362484
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-12-15
[patent_title] => 'SELF-BUFFERING PROTEIN FORMULATIONS'
[patent_app_type] => utility
[patent_app_number] => 15/227880
[patent_app_country] => US
[patent_app_date] => 2016-08-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 15
[patent_no_of_words] => 31312
[patent_no_of_claims] => 31
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15227880
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/227880 | SELF-BUFFERING PROTEIN FORMULATIONS | Aug 2, 2016 | Abandoned |
Array
(
[id] => 11270537
[patent_doc_number] => 20160333084
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-11-17
[patent_title] => 'METHODS AND COMPOSITIONS FOR MODULATION OF OLFML3 MEDIATED ANGIOGENESIS'
[patent_app_type] => utility
[patent_app_number] => 15/227931
[patent_app_country] => US
[patent_app_date] => 2016-08-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 27
[patent_figures_cnt] => 27
[patent_no_of_words] => 24788
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15227931
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/227931 | METHODS AND COMPOSITIONS FOR MODULATION OF OLFML3 MEDIATED ANGIOGENESIS | Aug 2, 2016 | Abandoned |
Array
(
[id] => 16275605
[patent_doc_number] => 10758612
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-09-01
[patent_title] => Antibodies to tumor associated complex N-glycans with terminal GlcNAcb residues and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 15/744658
[patent_app_country] => US
[patent_app_date] => 2016-07-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 29
[patent_no_of_words] => 21979
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 115
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15744658
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/744658 | Antibodies to tumor associated complex N-glycans with terminal GlcNAcb residues and methods of use thereof | Jul 14, 2016 | Issued |
Array
(
[id] => 11403040
[patent_doc_number] => 20170023579
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-01-26
[patent_title] => 'MULTIPLEX HER2 AND ESTROGEN RECEPTOR CO-STAINING ASSAYS FOR DETECTING TUMOR HETEROGENEITY'
[patent_app_type] => utility
[patent_app_number] => 15/201273
[patent_app_country] => US
[patent_app_date] => 2016-07-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 22
[patent_no_of_words] => 22520
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15201273
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/201273 | MULTIPLEX HER2 AND ESTROGEN RECEPTOR CO-STAINING ASSAYS FOR DETECTING TUMOR HETEROGENEITY | Jun 30, 2016 | Abandoned |
Array
(
[id] => 16058509
[patent_doc_number] => 10688178
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-06-23
[patent_title] => AntiPlexin A1 agonist antibody
[patent_app_type] => utility
[patent_app_number] => 15/741225
[patent_app_country] => US
[patent_app_date] => 2016-06-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 13
[patent_no_of_words] => 18321
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 143
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15741225
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/741225 | AntiPlexin A1 agonist antibody | Jun 29, 2016 | Issued |
Array
(
[id] => 11576842
[patent_doc_number] => 09632093
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2017-04-25
[patent_title] => 'Detecting neoplasm'
[patent_app_type] => utility
[patent_app_number] => 15/197105
[patent_app_country] => US
[patent_app_date] => 2016-06-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 12
[patent_no_of_words] => 15680
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 224
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15197105
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/197105 | Detecting neoplasm | Jun 28, 2016 | Issued |
Array
(
[id] => 12099240
[patent_doc_number] => 09856327
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-01-02
[patent_title] => 'Heterodimeric antibodies to CD3 X CD123'
[patent_app_type] => utility
[patent_app_number] => 15/186167
[patent_app_country] => US
[patent_app_date] => 2016-06-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 204
[patent_figures_cnt] => 212
[patent_no_of_words] => 30185
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15186167
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/186167 | Heterodimeric antibodies to CD3 X CD123 | Jun 16, 2016 | Issued |
Array
(
[id] => 11514345
[patent_doc_number] => 20170081420
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-03-23
[patent_title] => 'HETERODIMERIC ANTIBODIES TO CD3 X CD123'
[patent_app_type] => utility
[patent_app_number] => 15/185958
[patent_app_country] => US
[patent_app_date] => 2016-06-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 192
[patent_figures_cnt] => 192
[patent_no_of_words] => 26678
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15185958
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/185958 | Heterodimeric antibodies to CD3 X CD20 | Jun 16, 2016 | Issued |
Array
(
[id] => 11604475
[patent_doc_number] => 20170121777
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-05-04
[patent_title] => 'Method for the Diagnosis, Prognosis and Treatment of Prostate Cancer Metastasis'
[patent_app_type] => utility
[patent_app_number] => 15/183419
[patent_app_country] => US
[patent_app_date] => 2016-06-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 39016
[patent_no_of_claims] => 29
[patent_no_of_ind_claims] => 15
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15183419
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/183419 | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis | Jun 14, 2016 | Issued |
Array
(
[id] => 16518722
[patent_doc_number] => 10869924
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-12-22
[patent_title] => PD-L1 antagonist combination treatments
[patent_app_type] => utility
[patent_app_number] => 15/736615
[patent_app_country] => US
[patent_app_date] => 2016-06-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 26789
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15736615
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/736615 | PD-L1 antagonist combination treatments | Jun 14, 2016 | Issued |
Array
(
[id] => 13606951
[patent_doc_number] => 20180355024
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-12-13
[patent_title] => HETERO-DIMERIC MULTI-SPECIFIC ANTIBODY FORMAT
[patent_app_type] => utility
[patent_app_number] => 15/736747
[patent_app_country] => US
[patent_app_date] => 2016-06-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10259
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 228
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15736747
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/736747 | Hetero-dimeric multi-specific antibody format | Jun 14, 2016 | Issued |
Array
(
[id] => 14700655
[patent_doc_number] => 10378062
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-08-13
[patent_title] => Natural-killer/T-cell lymphoma (NKTCL) susceptibility prediction, diagnosis and therapy
[patent_app_type] => utility
[patent_app_number] => 15/174578
[patent_app_country] => US
[patent_app_date] => 2016-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 16
[patent_no_of_words] => 6009
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 184
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15174578
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/174578 | Natural-killer/T-cell lymphoma (NKTCL) susceptibility prediction, diagnosis and therapy | Jun 5, 2016 | Issued |